secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2021-08-13T23:59:59+00:00
Accession:  0001564590-21-044128
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q2 2021 net loss $24.5M; cash $339M; PC14586 trial enrollment ongoing
--------------------------------------------------------------------------------

- Net loss for H1 2021 was $24.5M vs $15.2M in H1 2020.
- Cash, cash equivalents & marketable securities $339.0M at June 30, 2021.
- R&D expenses $15.2M (H1 2021) vs $11.8M (H1 2020) on PC14586 development.
- Continued enrollment in Phase 1/2 trial of p53 Y220C reactivator PC14586.
- Activated 12 clinical trial sites across leading US oncology centers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000156459021044128/0001564590-21-044128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000156459021044128/pmvp-8k_20210813.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-044128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer